While first pilot studies evaluating brentuximab vedotin in adults with refractory testicular cancer have been initiated 10, to date, there are no data delineating bystander efficacy of the CD30‐conjugated tubulin toxin on CD30‐negative GCT cells. The gene discussed is TNFRSF8; the disease is testicular cancer.